These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 27321385)

  • 1. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
    Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
    Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Chen YW; Wang JS; Sheu WH; Lin SY; Lee IT; Song YM; Fu CP; Lee CL
    PLoS One; 2017; 12(2):e0171753. PubMed ID: 28182722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of sitagliptin with basal-plus insulin regimen versus insulin alone in non-critically ill hospitalized patients with type 2 diabetes: SITA-PLUS hospital trial.
    Gracia-Ramos AE; Cruz-Dominguez MDP; Madrigal-Santillán EO; Rojas-Martínez R; Morales-González JA; Morales-González Á; Hernández-Espinoza M; Vargas-Peñafiel J; Tapia-González MLÁ
    J Diabetes Complications; 2024 May; 38(5):108742. PubMed ID: 38581842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sitagliptin on glucose control in type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery.
    Shah A; Levesque K; Pierini E; Rojas B; Ahlers M; Stano S; Holter M; Dutia R; Belsley S; McGinty J; Laferrère B
    Diabetes Obes Metab; 2018 Apr; 20(4):1018-1023. PubMed ID: 29072800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled clinical trial of a combination therapy of vildagliptin plus an α-glucosidase inhibitor for patients with type II diabetes mellitus.
    Su Y; Su YL; Lv LF; Wang LM; Li QZ; Zhao ZG
    Exp Ther Med; 2014 Jun; 7(6):1752-1756. PubMed ID: 24926379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of vildagliptin in patients with type 2 diabetes undergoing hemodialysis.
    Mera J; Okada E; Okuda M; Ota T; Sibata S; Uchida S
    J Diabetes Metab Disord; 2015; 14():83. PubMed ID: 26550558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro cytogenetic assessment and comparison of vildagliptin and sitagliptin.
    Börçek Kasurka C; Elbistan M; Atmaca A; Atlı Şekeroğlu Z
    Cytotechnology; 2019 Dec; 71(6):1063-1077. PubMed ID: 31555935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness research using claims data: meticulous methods don't solve old problems.
    Ruzieh M
    Eur Heart J; 2024 Apr; 45(14):1284. PubMed ID: 38252975
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of the effect on antihyperglycaemic action of sitagliptin by plasma active form glucagon-like peptide-1.
    Kushiyama A; Kikuchi T; Tanaka K; Tahara T; Takao T; Onishi Y; Yoshida Y; Kawazu S; Iwamoto Y
    World J Diabetes; 2016 Jun; 7(11):230-8. PubMed ID: 27326345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacodynamic analysis of hemoglobin A1c-lowering effects by adding treatment of DPP-4 inhibitors (sitagliptin) in type 2 diabetes mellitus patients based on electronic medical records.
    Kakara M; Nomura H; Ezaki M; Fukae M; Hirota T; Matsubayashi S; Hirakawa M; Ieiri I
    J Diabetes Complications; 2016; 30(7):1282-6. PubMed ID: 27338508
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455-464.
    Mita T; Katakami N; Shimomura I; Watada H
    Diabetes Care; 2016 Jul; 39(7):e104-5. PubMed ID: 27330134
    [No Abstract]   [Full Text] [Related]  

  • 12. Comment on Mita et al. Sitagliptin Attenuates the Progression of Carotid Intima-Media Thickening in Insulin-Treated Patients With Type 2 Diabetes: The Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE): A Randomized Controlled Trial. Diabetes Care 2016;39:455-464.
    Maiorino MI; Bellastella G; Giugliano D; Esposito K
    Diabetes Care; 2016 Jul; 39(7):e102-3. PubMed ID: 27330133
    [No Abstract]   [Full Text] [Related]  

  • 13. Trelagliptin (SYR-472, Zafatek), Novel Once-Weekly Treatment for Type 2 Diabetes, Inhibits Dipeptidyl Peptidase-4 (DPP-4) via a Non-Covalent Mechanism.
    Grimshaw CE; Jennings A; Kamran R; Ueno H; Nishigaki N; Kosaka T; Tani A; Sano H; Kinugawa Y; Koumura E; Shi L; Takeuchi K
    PLoS One; 2016; 11(6):e0157509. PubMed ID: 27328054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of hypoglycemic treatment in type 2 diabetes stratified by age or diagnosed age: a meta-analysis.
    Cai X; Yang W; Chen Y; Gao X; Zhou L; Zhang S; Han X; Ji L
    Expert Opin Pharmacother; 2016 Aug; 17(12):1591-8. PubMed ID: 27322963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulphonylurea compared to DPP-4 inhibitors in combination with metformin carries increased risk of severe hypoglycemia, cardiovascular events, and all-cause mortality.
    Eriksson JW; Bodegard J; Nathanson D; Thuresson M; Nyström T; Norhammar A
    Diabetes Res Clin Pract; 2016 Jul; 117():39-47. PubMed ID: 27329021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 50 mg vildagliptin twice daily vs. 50 mg sitagliptin once daily on blood glucose fluctuations evaluated by long-term self-monitoring of blood glucose.
    Nomoto H; Kimachi K; Miyoshi H; Kameda H; Cho KY; Nakamura A; Nagai S; Kondo T; Atsumi T
    Endocr J; 2017 Apr; 64(4):417-424. PubMed ID: 28260702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Effect of Sitagliptin on Carotid Artery Atherosclerosis in Type 2 Diabetes: The PROLOGUE Randomized Controlled Trial.
    Oyama J; Murohara T; Kitakaze M; Ishizu T; Sato Y; Kitagawa K; Kamiya H; Ajioka M; Ishihara M; Dai K; Nanasato M; Sata M; Maemura K; Tomiyama H; Higashi Y; Kaku K; Yamada H; Matsuhisa M; Yamashita K; Bando YK; Kashihara N; Ueda S; Inoue T; Tanaka A; Node K;
    PLoS Med; 2016 Jun; 13(6):e1002051. PubMed ID: 27351380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
    Okamoto A; Yokokawa H; Sanada H; Naito T
    Drugs R D; 2016 Sep; 16(3):255-261. PubMed ID: 27333994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose Cotransporter 2 Inhibitor and a Low Carbohydrate Diet Affect Gluconeogenesis and Glycogen Content Differently in the Kidney and the Liver of Non-Diabetic Mice.
    Atageldiyeva K; Fujita Y; Yanagimachi T; Mizumoto K; Takeda Y; Honjo J; Takiyama Y; Abiko A; Makino Y; Haneda M
    PLoS One; 2016; 11(6):e0157672. PubMed ID: 27327650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
    Park SH; Nam JY; Han E; Lee YH; Lee BW; Kim BS; Cha BS; Kim CS; Kang ES
    Medicine (Baltimore); 2016 Aug; 95(32):e4543. PubMed ID: 27512877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.